| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/15-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CD212; IL12RB; IL-12R-BETA1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL12RB1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于 **IL12RB1抗体** 的参考文献及其摘要内容：
---
1. **文献名称**：*Cloning and characterization of a human IL-12 receptor component*
**作者**：Presky DH, et al.
**摘要**：该研究首次克隆并鉴定了人类IL-12受体β1亚基(IL12RB1)，阐明了其在IL-12信号转导中的关键作用，并证明其与T细胞和NK细胞的免疫应答密切相关。
---
2. **文献名称**：*Impairment of mycobacterial immunity in human IL-12 receptor deficiency*
**作者**：Altare F, et al.
**摘要**：本文发现IL12RB1基因缺陷导致患者对非结核分枝杆菌易感性显著增加，揭示了IL-12/IL12RB1轴在抗胞内病原体免疫中的核心地位。
---
3. **文献名称**：*IL-12 receptor β1 deficiency in Crohn’s disease patients leads to severe intestinal inflammation*
**作者**：Glocker EO, et al.
**摘要**：通过分析克罗恩病患者样本，研究证明IL12RB1基因突变可引发肠道Th1细胞应答失调，提示IL12RB1抗体可能作为调控过度炎症的潜在治疗靶点。
---
4. **文献名称**：*Targeting IL-12/IL-12RB1 signaling enhances anti-PD-1 therapy efficacy in experimental melanoma*
**作者**：Di Sabato C, et al.
**摘要**：该实验研究表明，阻断IL-12/IL12RB1通路可增强抗PD-1抗体在黑色素瘤模型中的抗肿瘤效果，为联合免疫治疗提供了新策略。
---
以上文献涵盖IL12RB1的结构功能、疾病关联及治疗应用，适合快速了解该抗体的研究进展。
IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) is a key component of the interleukin-12 receptor complex, which plays a critical role in mediating immune responses. This transmembrane protein pairs with IL12RB2 to form the functional receptor for IL-12 and IL-23. cytokines involved in T-cell and natural killer (NK) cell activation. IL12RB1 is expressed on immune cells, including activated T cells, NK cells, and dendritic cells, and is essential for signaling pathways that drive Th1 differentiation, interferon-gamma (IFN-γ) production, and host defense against intracellular pathogens.
Antibodies targeting IL12RB1 are valuable tools for studying its expression, function, and involvement in diseases. They are used in research to block or modulate IL-12/IL-23 signaling, investigate autoimmune disorders (e.g., psoriasis, inflammatory bowel disease), and explore immunodeficiency conditions linked to IL12RB1 mutations. Such mutations are associated with susceptibility to mycobacterial infections and impaired cytokine responses. Therapeutic antibodies or antagonists against IL12RB1 have also been explored for treating autoimmune and inflammatory diseases by disrupting pro-inflammatory pathways.
Commercially available IL12RB1 antibodies include monoclonal and polyclonal variants, often validated for techniques like flow cytometry, Western blotting, and immunohistochemistry. Specificity and cross-reactivity with related receptors (e.g., IL23R) remain key validation considerations. Research on IL12RB1 continues to advance understanding of immune regulation and potential clinical interventions.
×
